|Liver and Spleen Tumours in Rats After Injection of Zirconotrast to Which Different Amounts of Th-228/Th-230 Were Added.
|Published: Open access to everyone
|BIOLOGICAL SAMPLE AVAILABLE
|Purpose: To determine the respective roles of the radioactive and chemical component in Thorotrast induced liver and spleen damage. The radioactive Th-228/Th-230 was added to the Zirconotrast Zr-dioxide to obtain different levels alpha-energy emissions compared to an original Thorotrast solution.
Status: 1980-1984, terminated
Treatment: Single i.v. injection of 120 μl of Zirconotrast (Zr-dioxide) to which different amounts of Th-230/Th-228 had been added to obtain 0, 1, 2.5, 5, 10 and 25 times the alpha-energy emission of an original Thorotrast solution.
Dosimetry: Activity injected
Endpoints: Life-span study (spontaneous death) with macroscopic/microscopic pathology
Animal: Female Wistar rats aged 12 ± 2 weeks at the injection
Results: The distribution of Zirconotrast in the liver of the rats was similar to that of Thorotrast in humans. The number of liver and spleen tumours increased by a factor of 15 in the highest dose-rate group compared to controls. The frequency of these tumours showed a dependence on the dose-rate, but was not correlated with the number of injected particles. The pure nonradioactive colloid did not induce an excess of liver and spleen tumours nor did it increase tumour incidence when added to radioactive colloid compared to the radioactive colloid give alone delivering the same dose rate. No excess lung tumours due to the exhalation of Rn-220 was observed.
FFPE Blocks are available at HMGU.
|Link to data and details in ERA
|LINK TO FILE